共 302 条
[1]
Burris HA(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[2]
Moore MJ(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960-1966
[3]
Andersen J(2011)FOLFIRINOX vs gemcitabine for metastatic pancreatic cancer N Engl J Med 364 1817-1825
[4]
Green MR(1996)Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548-557
[5]
Rothenberg ML(1987)Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts Jpn J Cancer Res 78 748-755
[6]
Modiano MR(1993)Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004-4009
[7]
Cripps MC(2008)A late phase II study of S-1 for metastatic pancreatic cancer Cancer Chemother Pharmacol 61 615-621
[8]
Portenoy RK(2009)A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer Cancer Chemother Pharmacol 63 313-319
[9]
Storniolo AM(2011)Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer Cancer Chemother Pharmacol 67 249-254
[10]
Tarassoff P(2011)Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 80 119-125